# Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

> **NCT03020095** · PHASE2 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Ravidasvir
- **DRUG:** Danoprevir
- **DRUG:** Ritonavir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT03020095
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-08
- **Final completion:** 2017-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020095, "Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03020095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*